Dynamic Technology Lab Private Ltd Buys Shares of 13,248 Twist Bioscience Co. (NASDAQ:TWST)

Dynamic Technology Lab Private Ltd bought a new position in Twist Bioscience Co. (NASDAQ:TWST) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 13,248 shares of the company’s stock, valued at approximately $599,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Algert Global LLC lifted its stake in Twist Bioscience by 59.7% in the third quarter. Algert Global LLC now owns 43,592 shares of the company’s stock worth $1,969,000 after acquiring an additional 16,292 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Twist Bioscience by 4.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 524,942 shares of the company’s stock valued at $23,717,000 after purchasing an additional 24,582 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of Twist Bioscience by 215.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company’s stock worth $1,324,000 after purchasing an additional 20,035 shares during the period. Intech Investment Management LLC bought a new position in shares of Twist Bioscience during the third quarter valued at approximately $714,000. Finally, Jennison Associates LLC boosted its stake in shares of Twist Bioscience by 29.6% during the third quarter. Jennison Associates LLC now owns 377,894 shares of the company’s stock valued at $17,073,000 after purchasing an additional 86,399 shares in the last quarter.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. TD Cowen restated a “buy” rating and set a $58.00 target price on shares of Twist Bioscience in a report on Tuesday. Leerink Partners upped their price objective on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. Scotiabank lifted their target price on Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a research note on Tuesday, November 19th. Barclays reduced their target price on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday, November 19th. Finally, Evercore ISI raised their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $51.00.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 1,730 shares of the business’s stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $46.94, for a total transaction of $81,206.20. Following the sale, the chief executive officer now owns 495,523 shares in the company, valued at approximately $23,259,849.62. The trade was a 0.35 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Dennis Cho sold 1,507 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $48.00, for a total value of $72,336.00. Following the completion of the transaction, the insider now owns 91,163 shares of the company’s stock, valued at approximately $4,375,824. The trade was a 1.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 98,118 shares of company stock worth $4,391,151. 3.92% of the stock is owned by corporate insiders.

Twist Bioscience Stock Up 4.3 %

TWST opened at $48.32 on Friday. The firm’s 50-day moving average price is $43.78 and its 200-day moving average price is $46.22. The company has a market cap of $2.87 billion, a P/E ratio of -13.42 and a beta of 1.78. Twist Bioscience Co. has a 52-week low of $23.07 and a 52-week high of $60.90.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.